Erest. References 1. 2. Enzinger, P.C.; Mayer, R.J. Esophageal cancer. N. Engl. J. Med. 2003, 349, 2241?252. Zhou, J.; Xiang, Q.; Tao, R.; Yang, J.; Lin, P.; Wu, M. Analysis on surveillance of trigger death in Jiangsu province for the duration of 2007. Jiangsu J. Prev. Med. 2008, 19, 74?5.Int. J. Mol. Sci. 2013, 14 3.4. five. 6. 7. eight. 9. 10. 11. 12.13.14.15.16. 17. 18. 19.20. 21.Rice, T.W.; Rusch, V.W.; Apperson-Hansen, C.; Allen, M.S.; Chen, L.Q.; Hunter, J.G.; Kesler, K.A.; Law, S.; Lerut, T.E.; Reed, C.E.; et al. Worldwide esophageal cancer collaboration. Dis. Esophagus 2009, 22, 1?. Nicholson, J.K.; Lindon, J.C. Systems biology: Metabonomics. Nature 2008, 455, 1054?056. Idle, J.R.; Gonzalez, F.J. Metabolomics. Cell Metab. 2007, 6, 348?51. Syggelou, A.; Iacovidou, N.; Atzori, L.; Xanthos, T.; Fanos, V. Metabolomics in the creating human becoming. Pediatr. Clin. N. Am. 2012, 59, 1039?058. Johnson, C.H.; Gonzalez, F.J. Challenges and opportunities of metabolomics. J. Cell. Physiol. 2012, 227, 2975?981. Ellis, D.I.; Dunn, W.B.; Griffin, J.L.; Allwood, J.W.; Goodacre, R. Metabolic fingerprinting as a diagnostic tool. Pharmacogenomics 2007, eight, 1243?266. Ma, Y.; Zhang, P.; Yang, Y.; Wang, F.; Qin, H. Metabolomics within the fields of oncology: A evaluation of current study. Mol. Biol. Rep. 2012, 39, 7505?511. O’Connell, T.M. Recent advances in metabolomics in oncology. Bioanalysis 2012, 4, 431?51. Mamas, M.; Dunn, W.B.; Neyses, L.; Goodacre, R. The part of metabolites and metabolomics in clinically applicable biomarkers of illness. Arch. Toxicol. 2011, 85, 5?7. Claudino, W.M.; Quattrone, A.; Biganzoli, L.; Pestrin, M.; Bertini, I.; Di Leo, A. Metabolomics: Out there outcomes, present study projects in breast cancer, and future applications. J. Clin. Oncol. 2007, 25, 2840?846. Qiu, Y.; Cai, G.; Su, M.; Chen, T.; Zheng, X.; Xu, Y.; Ni, Y.; Zhao, A.; Xu, L.X.; Cai, S.; et al. Serum metabolite profiling of human colorectal cancer employing gc-tofms and uplc-qtofms. J. Proteome. Res. 2009, eight, 4844?850. Zhou, J.; Xu, B.; Huang, J.; Jia, X.; Xue, J.; Shi, X.; Xiao, L.; Li, W. 1h nmr-based metabonomic and pattern recognition evaluation for detection of oral squamous cell carcinoma. Clin. Chim. Acta 2009, 401, eight?three. Sreekumar, A.; Poisson, L.M.; Rajendiran, T.M.; Khan, A.P.; Cao, Q.; Yu, J.; Laxman, B.; Mehra, R.; Lonigro, R.J.; Li, Y.; et al. Metabolomic profiles delineate potential function for sarcosine in prostate cancer progression. Nature 2009, 457, 910?14. Zhang, A.; Sun, H.; Wang, X. Serum metabolomics as a novel diagnostic approach for disease: A systematic overview.1,3,6,8-Tetrakis[p-benzoic acid]pyrene Order Anal.3-Bromopyridazine uses Bioanal.PMID:23614016 Chem. 2012, 404, 1239?245. Van Meer, G.; de Kroon, A.I. Lipid map of your mammalian cell. J. Cell Sci. 2011, 124, five?. Wymann, M.P.; Schneiter, R. Lipid signalling in disease. Nat. Rev. Mol. Cell Biol. 2008, 9, 162?76. Dueck, D.A.; Chan, M.; Tran, K.; Wong, J.T.; Jay, F.T.; Littman, C.; Stimpson, R.; Choy, P.C. The modulation of choline phosphoglyceride metabolism in human colon cancer. Mol. Cell. Biochem. 1996, 162, 97?03. Monteggia, E.; Colombo, I.; Guerra, A.; Berra, B. Phospholipid distribution in murine mammary adenocarcinomas induced by activated neu oncogene. Cancer Detect. Prev. 2000, 24, 207?11. Dobrzynska, I.; Szachowicz-Petelska, B.; Sulkowski, S.; Figaszewski, Z. Alterations in electric charge and phospholipids composition in human colorectal cancer cells. Mol. Cell. Biochem. 2005, 276, 113?19.Int. J. Mol. Sci. 2013,22. Ruiz-Cabello, J.; Cohen, J.S. Phospholipid metabolites as indicators of.